Ranibizumab

Drug #2191

Ranibizumab belongs to growth factors vascular endothelial A (VEGF-A) antagonists. It works by blocking the abnormal growth of blood vessels and leakage into the eye(s) that can loss vision in people with wet AMD i.e. age-related macular degeneration.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin.

Molecular Weight: 48 · Solubility in Water: soluble · Non-proprietary name: Ranibizumab · pH: 5.5.

Pharmacokinetics

Elimination: plasma half-life is 2.88 days.

Indications

Ranibizumab is primarily indicated in conditions like age-related macular degeneration..

Contraindications

Ranibizumab is contraindicated in conditions like Hypersensitivity, Ocular inflammation.

Dosage

Ranibizumab's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
0.5 mg	0.5 mg	—	intravitreal	once a month (approximately 28 days). Although less effective, treatment may be reduced to one injection every three months after the first four injections if monthly injections are not feasible. Compared to continued monthly dosing, dosing every 3 months will lead to an approximate 5-letter (1-line) loss of visual acuity benefit, on average, over the following 9 months. Patients should be evaluated regularly. Adequate anesthesia and a broad-spectrum microbicide should be given prior to the intravitreal injection.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

None recorded.

Side Effects

Ranibizumab is known to cause more or less tolerable side effects which are usually transient. These include Blepharitis , Cataract, Conjunctival hyperemia, Dry eye, Eye irritation, Eye Pain , Eye Pruritis, Foreign body sensation in eyes, Intraocular inflammation, Intraocular pressure, Lacrimation, Maculopathy, Ocular hyperemia, Retinal disorder, Visual disturbances, Vitreous detachment, Vitreous floaters.

Warnings / Precautions

Pregnancy Category C. It is also not known whether ranibizumab can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. It should be given to a pregnant woman only if clearly needed. aution should be exercised when Ranibizumab is administered to a nursing woman. No notable difference in treatment effect was seen with increasing age in any of the studies.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Inj

10 mg/ml

Storage Conditions

Ranibizumab should be stored Inj.

Drug Classification

1.21.7 — Other ophthalmologicals

Manufacturers

Manufacturers of Ranibizumab in Pakistan:

Novartis